Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Research enables artificial intelligence approach to create AAV capsids for gene therapies


Dyno Therapeutics founders and collaborators demonstrate machine-guided AAV capsid engineering with the potential to transform gene therapy

Dyno Therapeutics, a biotechnology company pioneering use of artificial intelligence in gene therapy, today announced a publication in the journal Science that demonstrates the power of a comprehensive machine-guided approach to engineer improved capsids for gene therapy delivery.

Improved AAV vector capsid for gene therapy engineered with a new machine-guided approach shows, in red, improvements in efficiency of viral production based on the average effect of insertions at all possible amino acid positions, with white showing neutral and blue showing deleterious positions. (Left: capsid viewed from outside, Right: cut-out to reveal inner positions).

Credit: Eric Kelsic, Dyno Therapeutics

The research was conducted by Dyno co-founders Eric D. Kelsic, Ph.D. and Sam Sinai, Ph.D., together with colleague Pierce Ogden, Ph.D., at Harvard's Wyss Institute for Biologically Inspired Engineering and the Harvard Medical School laboratory of George M. Church, Ph.D., a Dyno scientific co-founder. The publication, entitled "Comprehensive AAV capsid fitness landscape reveals a viral gene and enables machine-guided design," is available here:

AAV capsids are presently the most commonly used vector for gene therapy because of their established ability to deliver genetic material to patient organs with a proven safety profile.

However, there are only a few naturally occurring AAV capsids, and they are deficient in essential properties for optimal gene therapy, such as targeted delivery, evasion of the immune system, higher levels of viral production, and greater transduction efficiency. Starting at Harvard in 2015, the authors set out to overcome the limitations of current capsids by developing new machine-guided technologies to rapidly and systematically engineer a suite of new, improved capsids for widespread therapeutic use.

In the research published in Science, the authors demonstrate the advance of their unique machine-guided approach to AAV engineering. Previous approaches have been limited by the difficulty of altering a complex capsid protein without breaking its function and by the general lack of knowledge regarding how AAV capsids interact with the body. Historically, rather than addressing this challenge directly, the most popular approaches to capsid engineering have taken a roundabout solution: generating libraries of new capsids by making random changes to the protein. However, since most random changes to the capsid actually result in decreased function, such random libraries contain few viable capsids, much less improved ones. Recognizing the limitation of conventionally generated capsid libraries, the authors implemented a machine-guided approach that gathered a vast amount of data using new high-throughput measurement technologies to teach them how to build better libraries and, ultimately, lead to synthetic capsids with optimized delivery properties.

Focusing on the AAV2 capsid, the authors generated a complete landscape of all single codon substitutions, insertions and deletions, then measured the functional properties important for in vivo delivery. They then used a machine-guided approach, leveraging these data to efficiently generate diverse libraries of AAV capsids with multiple changes that targeted the mouse liver and that outperformed AAVs generated by conventional random mutagenesis approaches. In the process, the authors' systematic efforts unexpectedly revealed the existence of a previously-unrecognized protein encoded within the sequence of all the most popular AAV capsids, which they termed membrane-associated accessory protein (MAAP). The authors believe that the protein plays a role in the natural life cycle of AAV.

"This is just the beginning of machine-guided engineering of AAV capsids to transform gene therapy," underscores co-author Sam Sinai, Ph.D., Lead Machine Learning Scientist and co-founder of Dyno Therapeutics. "The success of the simple linear models used in this study has led us to pursue more data and higher capacity machine learning models, where the potential for improvement in capsid designs feels boundless."

"The results in the Science publication demonstrate, for the first time, the power of linking a comprehensive set of advanced techniques - large scale DNA synthesis, pooled in vitro and in vivo screens, next-generation sequencing readouts, and iterative machine-guided capsid design - to generate optimized synthetic AAV capsids," explains co-first and co-corresponding author Eric D. Kelsic, Ph.D., CEO and co-founder of Dyno Therapeutics. "At Dyno, our team is committed to advancing these technologies to identify capsids that meet the urgent needs of patients who can benefit from gene therapies."


About Dyno Therapeutics

Dyno Therapeutics is a pioneer in applying artificial intelligence to gene therapy. The company's powerful and proprietary genetic engineering platform is designed to rapidly and systematically develop improved AAV capsids that redefine the gene therapy landscape. Dyno was founded by experienced biotech entrepreneurs and leading scientists in the fields of synthetic biology, gene therapy, and machine learning. The company is located in Cambridge, Massachusetts. For additional information, please visit the company website at

1. Ogden P.J., Kelsic E.D., Sinai S., Church G.M. Comprehensive AAV capsid fitness landscape reveals a viral gene and enables machine-guided design. Science. 2019 Nov 29;366(6469):1139-43. doi: 10.1126/science.aaw2900

Media Contact

Kathryn Morris

Kathryn Morris | EurekAlert!

Further reports about: gene therapy machine learning synthetic

More articles from Life Sciences:

nachricht When plants bloom
29.11.2019 | Max-Planck-Institut für Molekulare Pflanzenphysiologie

nachricht Harnessing the power of CRISPR in space and time
29.11.2019 | IMBA - Institut für Molekulare Biotechnologie der Österreichischen Akademie der Wissenschaften GmbH

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: How do scars form? Fascia function as a repository of mobile scar tissue

Abnormal scarring is a serious threat resulting in non-healing chronic wounds or fibrosis. Scars form when fibroblasts, a type of cell of connective tissue, reach wounded skin and deposit plugs of extracellular matrix. Until today, the question about the exact anatomical origin of these fibroblasts has not been answered. In order to find potential ways of influencing the scarring process, the team of Dr. Yuval Rinkevich, Group Leader for Regenerative Biology at the Institute of Lung Biology and Disease at Helmholtz Zentrum München, aimed to finally find an answer. As it was already known that all scars derive from a fibroblast lineage expressing the Engrailed-1 gene - a lineage not only present in skin, but also in fascia - the researchers intentionally tried to understand whether or not fascia might be the origin of fibroblasts.

Fibroblasts kit - ready to heal wounds

Im Focus: McMaster researcher warns plastic pollution in Great Lakes growing concern to ecosystem

Research from a leading international expert on the health of the Great Lakes suggests that the growing intensity and scale of pollution from plastics poses serious risks to human health and will continue to have profound consequences on the ecosystem.

In an article published this month in the Journal of Waste Resources and Recycling, Gail Krantzberg, a professor in the Booth School of Engineering Practice...

Im Focus: Machine learning microscope adapts lighting to improve diagnosis

Prototype microscope teaches itself the best illumination settings for diagnosing malaria

Engineers at Duke University have developed a microscope that adapts its lighting angles, colors and patterns while teaching itself the optimal...

Im Focus: Small particles, big effects: How graphene nanoparticles improve the resolution of microscopes

Conventional light microscopes cannot distinguish structures when they are separated by a distance smaller than, roughly, the wavelength of light. Superresolution microscopy, developed since the 1980s, lifts this limitation, using fluorescent moieties. Scientists at the Max Planck Institute for Polymer Research have now discovered that graphene nano-molecules can be used to improve this microscopy technique. These graphene nano-molecules offer a number of substantial advantages over the materials previously used, making superresolution microscopy even more versatile.

Microscopy is an important investigation method, in physics, biology, medicine, and many other sciences. However, it has one disadvantage: its resolution is...

Im Focus: Atoms don't like jumping rope

Nanooptical traps are a promising building block for quantum technologies. Austrian and German scientists have now removed an important obstacle to their practical use. They were able to show that a special form of mechanical vibration heats trapped particles in a very short time and knocks them out of the trap.

By controlling individual atoms, quantum properties can be investigated and made usable for technological applications. For about ten years, physicists have...

All Focus news of the innovation-report >>>



Industry & Economy
Event News

First International Conference on Agrophotovoltaics in August 2020

15.11.2019 | Event News

Laser Symposium on Electromobility in Aachen: trends for the mobility revolution

15.11.2019 | Event News

High entropy alloys for hot turbines and tireless metal-forming presses

05.11.2019 | Event News

Latest News

When plants bloom

29.11.2019 | Life Sciences

Harnessing the power of CRISPR in space and time

29.11.2019 | Life Sciences

New evolutionary insights into the early development of songbirds

29.11.2019 | Life Sciences

Science & Research
Overview of more VideoLinks >>>